Fondazione IRCCS Istituto Neurologico 'Carlo Besta', Milano, Italy; Istituto di Neurologia, Università Cattolica, Milano, Italy.
Eur J Neurol. 2015 Mar;22(3):426-e32. doi: 10.1111/ene.12596. Epub 2014 Nov 10.
There is increasing evidence that deep brain stimulation (DBS) of the globus pallidus internus (GPi) is effective in patients with idiopathic or inherited generalized dystonia. There is comparatively less experience about the effects of GPi DBS on acquired dystonia, particularly dystonia due to cerebral palsy (DCP). Clinical and demographic outcome predictors for DBS in dystonia syndromes are also poorly defined. Our aim was to examine the efficacy and safety of GPi DBS for the treatment of generalized DCP.
Fifteen patients with DCP up to 6.2 years after DBS surgery were studied. Only mild limb spasticity or mild static brain magnetic resonance imaging abnormalities were acceptable for inclusion. Dystonia severity and disability were assessed by the Burke-Fahn-Marsden dystonia rating scale (BFMDRS), and health-related quality of life was assessed by the Short Form General Health Survey (SF-36) scale. The amount of energy delivered was calculated, and adverse events and side effects were collected.
At last follow-up, BFMDRS motor score improved on average by 49.5%, and the disability score improved by 30%. Health-related quality of life improved in most patients. Age at implant, age at onset and disease duration did not correlate to outcome, whilst higher pre-operative dystonia severity and occurrence of spasticity were associated with poorer outcome. The patients received a stable amount of energy after the first 2 years post-implant and throughout all the observation period. There were few serious adverse events or side effects.
The outcome was encouraging in the majority of DCP patients, with a stable outlook and a good safety profile.
越来越多的证据表明,深部脑刺激(DBS)对特发性或遗传性全身性肌张力障碍患者有效。对于获得性肌张力障碍,特别是脑瘫(CP)引起的肌张力障碍,DBS 的经验相对较少。DBS 治疗肌张力障碍综合征的临床和人口统计学结果预测因素也尚未明确。我们的目的是研究苍白球 internus(GPi)DBS 治疗广泛性 CP 的疗效和安全性。
研究了 15 例 CP 患者,这些患者在 DBS 手术后 6.2 年内接受了治疗。只有轻度肢体痉挛或轻度静态脑磁共振成像异常才能被纳入。采用 Burke-Fahn-Marsden 肌张力障碍评定量表(BFMDRS)评估肌张力障碍严重程度和残疾程度,采用 Short Form General Health Survey(SF-36)量表评估健康相关生活质量。计算输送的能量量,并收集不良事件和副作用。
在最后一次随访时,BFMDRS 运动评分平均提高了 49.5%,残疾评分提高了 30%。大多数患者的健康相关生活质量都有所改善。植入年龄、发病年龄和病程与结果无关,而术前肌张力障碍严重程度较高和痉挛发生与较差的结果相关。患者在植入后最初的 2 年内以及整个观察期内接受了稳定的能量输送。严重不良事件或副作用很少见。
大多数 CP 患者的结果令人鼓舞,具有稳定的前景和良好的安全性。